TyG-BMI predicts nonalcoholic fatty liver disease in nonobese individuals
Triglyceride and glucose index in combination with body mass index (TyG-BMI) is an effective marker in detecting nonalcoholic fatty liver disease (NAFLD) in nonobese individuals, a new observational study has found.
The study included 6,809 nonobese Chinese adults (mean age 48.4±15.1 years; mean BMI, 22.0±2.0 kg/m2) with complete health examination data. Exclusion criteria were autoimmune hepatic diseases, chronic hepatic diseases, hepatic virus infections and diabetes or dyslipidaemia medications.
NAFLD diagnoses were delivered according to the Asia-Pacific Working Party guidelines. All participants underwent anthropometric measurements and routine biochemical laboratory tests.
NAFLD prevalence was 2.2 percent in the first TyG-BMI quartile and increased to 9.0 percent in the second. The prevalence further increased to 27.8 and 56.7 percent in the third and fourth quartiles of TyG-BMI, respectively.
Compared with participants in the first TyG-BMI quartile, those in the second (odds ratio [OR], 2.44; 95 percent CI, 1.6 to 3.6), third (OR, 6.4; 4.2 to 9.7) and fourth (OR, 15.3; 9.8 to 23.9) had higher risks of NAFLD after adjusting for blood pressure, serum biomarkers and BMI.
In the fully adjusted model, every 1-standard deviation increase in TyG-BMI also increased the risk of NAFLD (OR, 3.4; 3.0 to 3.9).
The diagnostic value of TyG-BMI (area under the receiver operating curve [AUROC], 0.835; 0.824 to 0.845; p<0.0001) was greater than that of BMI (AUROC, 0.783; 0.771 to 0.794; p<0.0001), TyG (AUROC 0.764; 0.751 to 0.777; p<0.0001), triglycerides (AUROC, 0.753; 0.739 to 0.766; p<0.0001) and fasting plasma glucose (AUROC, 0.625; 0.609 to 0.641; p<0.0001).